RAPT Therapeutics (RAPT) Operating Income (2020 - 2023)
Historic Operating Income for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$33.2 million.
- Therapeutics' Operating Income fell 3596.25% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 4809.95%. This contributed to the annual value of -$127.1 million for FY2023, which is 4809.95% down from last year.
- As of Q4 2023, Therapeutics' Operating Income stood at -$33.2 million, which was down 3596.25% from -$33.9 million recorded in Q3 2023.
- In the past 5 years, Therapeutics' Operating Income registered a high of -$12.5 million during Q2 2020, and its lowest value of -$33.9 million during Q3 2023.
- In the last 4 years, Therapeutics' Operating Income had a median value of -$18.7 million in 2021 and averaged -$21.0 million.
- Per our database at Business Quant, Therapeutics' Operating Income plummeted by 1696.97% in 2022 and then tumbled by 5646.74% in 2023.
- Quarter analysis of 4 years shows Therapeutics' Operating Income stood at -$13.1 million in 2020, then crashed by 37.82% to -$18.0 million in 2021, then crashed by 35.47% to -$24.4 million in 2022, then crashed by 35.96% to -$33.2 million in 2023.
- Its last three reported values are -$33.2 million in Q4 2023, -$33.9 million for Q3 2023, and -$28.4 million during Q2 2023.